Zanzalintinib for advanced bladder cancer after prior therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has worsened after previous treatments. The goal is to see if zanzalintinib can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced urothelial cancer (bladder cancer type) that has spread and cannot be removed by surgery.
- Your cancer has gotten worse after 1 to 3 previous treatments, including enfortumab vedotin (EV) and a PD-1/PD-L1 inhibitor (like pembrolizumab or atezolizumab).
- You have not had a VEGF inhibitor (like bevacizumab or sunitinib) before.
- Your general health is good enough that you can take care of yourself (ECOG performance status 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This study tests a new drug called zanzalintinib in men with advanced prostate cancer (metastatic castration-resistant prostate cancer) who have already received Pluvicto treatment. The goal is to see if this drug can help slow or stop cancer growth when other hormone therapies are no longer working.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.